NAD+ is involved in cellular processes, but a biological role is not proof that buying an NAD+ product changes aging. The key questions are which substance was tested, by which route, in whom and for what outcome.
An oral precursor such as nicotinamide riboside is not the same purchase as a compounded NAD+ nasal spray, topical cream or injection. Mochi lists all three NAD+ routes. Its public catalog says they are compounded and not FDA approved for a specific indication. Those are catalog and status descriptions, not independent evidence that any form improves longevity.
For an informed purchase decision, ask for the exact product formula, route, amount per package, intended outcome, trial in a relevant population and total ongoing charge. The public Mochi cards omit some concentration and package details. Treat an advertised starting amount as incomplete until the exact checkout and refill terms are clear.
By Designing Longevity · Sources checked October 15, 2026 · How we compare
Some human biomarker evidence; the cited trial did not show a cognitive benefit on its main conventional measure.
The question to answer: What real-world outcome improved in a relevant trial?
Mochi lists a topical form, but oral precursor results cannot be transferred to skin application.
The question to answer: What outcome was tested for this exact cream?
Mochi lists a needle-free form; that description does not establish healthspan benefit.
The question to answer: Is there a relevant human trial for this nasal formulation?
A separate safety and evidence decision, with no longevity benefit established here.
The question to answer: How are sourcing, sterility and reactions handled?
A randomized crossover trial studied oral nicotinamide riboside in older adults with subjective cognitive decline or mild cognitive impairment. After eight weeks, researchers reported a difference in a plasma Alzheimer-related marker, but no significant between-group difference in their conventional cognitive test, other listed plasma markers, digital cognition score or step count. The authors called for a larger, longer study.
This trial does not answer whether a person without those characteristics will feel more energetic or live longer. It also cannot be used as evidence for a different ingredient, dose or route. NIA cautions that studied longevity compounds, including NAD, have not been proved to extend human lifespan or healthspan.
Oral NR aims to raise NAD+ through a precursor. A compounded NAD+ cream is applied to skin; a nasal spray is delivered through the nose; an injection enters the body by a different route. Each would need its own relevant human study, finished-product quality information and safety assessment. The absence of that evidence should stay visible instead of being filled by a general explanation of NAD biology.
FDA has warned about using unsuitable ingredients in sterile NAD+ compounding and has received reports of severe reactions after injectable products. That notice concerns a specific safety problem; it does not prove every product is contaminated. It does mean an injectable offer deserves direct questions about sterile preparation and adverse-event response.
Mochi lists topical, nasal and injectable compounded NAD+ products. Ask for the full formulation, what the displayed amount means, the package quantity, the clinical goal and the final terms for your plan. These details help you understand the purchase, but they still cannot turn an oral NR trial into evidence for another route.
No. A laboratory change needs to be connected to a meaningful human outcome in a relevant trial.
No. It is a different product and route. The oral trial cannot tell you its clinical effect.
The cited NIA review says NAD and other studied compounds have not been proved to extend human lifespan or healthspan.
We start with a reader’s decision, then separate published facts from our judgment. Government and professional sources support health explanations; a brand’s page supports what it lists, charges or promises. We have not tested these products or assessed individual treatment suitability.
We compare the decision, the studied outcome, the route and the commitment. A laboratory marker is not the same as better daily function, and a study of one formulation cannot establish results for another. We do not assign clinical stars to these options.
Prices and stock reflect the dated check, with missing facts shown explicitly. We withhold expired quotations and product-shopping links that lack the required label review. Monthly editions advance after a completed source check. Product source links use the brands’ public URLs. This content is not medically reviewed.
Linked guides keep their own source dates and limitations.